JPMorgan Chase & Co. Trims U.S. Physical Therapy (NYSE:USPH) Target Price to $99.00

U.S. Physical Therapy (NYSE:USPH) had its price objective decreased by JPMorgan Chase & Co. from $108.00 to $99.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 16.29% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. CJS Securities upgraded shares of U.S. Physical Therapy from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 19th. TheStreet lowered U.S. Physical Therapy from a “b-” rating to a “c+” rating in a research report on Wednesday, October 4th. Barrington Research cut their price target on U.S. Physical Therapy from $124.00 to $111.00 and set an “outperform” rating for the company in a research note on Thursday, November 9th. Finally, StockNews.com raised U.S. Physical Therapy from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $116.00.

U.S. Physical Therapy Stock Down 0.3 %

U.S. Physical Therapy stock traded down $0.24 during mid-day trading on Friday, hitting $85.13. The company’s stock had a trading volume of 37,413 shares, compared to its average volume of 91,952. U.S. Physical Therapy has a 52-week low of $78.08 and a 52-week high of $124.11. The company has a market cap of $1.28 billion, a PE ratio of 49.49, a price-to-earnings-growth ratio of 5.25 and a beta of 1.38. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.77 and a quick ratio of 2.77. The firm’s 50 day moving average is $89.09 and its 200 day moving average is $103.28.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $150.00 million during the quarter, compared to analyst estimates of $148.85 million. U.S. Physical Therapy had a net margin of 5.11% and a return on equity of 9.03%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.58 earnings per share. On average, analysts anticipate that U.S. Physical Therapy will post 2.54 earnings per share for the current year.

Insider Buying and Selling at U.S. Physical Therapy

In other news, Director Kathleen A. Gilmartin bought 1,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was purchased at an average price of $82.34 per share, with a total value of $82,340.00. Following the transaction, the director now directly owns 15,480 shares in the company, valued at $1,274,623.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Kathleen A. Gilmartin bought 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of $82.34 per share, for a total transaction of $82,340.00. Following the purchase, the director now directly owns 15,480 shares in the company, valued at $1,274,623.20. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, COO Graham D. Reeve sold 1,500 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $87.39, for a total transaction of $131,085.00. Following the transaction, the chief operating officer now directly owns 7,801 shares of the company’s stock, valued at approximately $681,729.39. The disclosure for this sale can be found here. Corporate insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in USPH. BlackRock Inc. grew its holdings in shares of U.S. Physical Therapy by 9.3% in the 2nd quarter. BlackRock Inc. now owns 2,203,592 shares of the company’s stock worth $267,494,000 after purchasing an additional 188,188 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its position in U.S. Physical Therapy by 0.9% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,509,045 shares of the company’s stock valued at $183,183,000 after buying an additional 13,531 shares in the last quarter. Morgan Stanley grew its stake in U.S. Physical Therapy by 3.9% during the third quarter. Morgan Stanley now owns 979,576 shares of the company’s stock worth $89,857,000 after buying an additional 36,680 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of U.S. Physical Therapy by 1.1% during the first quarter. Vanguard Group Inc. now owns 927,480 shares of the company’s stock worth $92,238,000 after buying an additional 10,015 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of U.S. Physical Therapy by 0.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 915,831 shares of the company’s stock valued at $74,210,000 after acquiring an additional 3,618 shares during the last quarter.

About U.S. Physical Therapy

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.